Clinical trial updates

Ferriprox®

Less than a minute
  • Product Information

    Product Information

    Scientific name: Deferiprone
    Brand name: Ferriprox
    RESPONSIBLE: Chiesi Farmaceutici S.p.A.

  • Clinical Trial/Study Information

    Clinical Trial/Study Information

    Last update: 22/6/2023
    Trial Name: N/A
    Code: N/A
    Phase: N/A
    Eligible patient diagnosis: N/A
    No. of Patients enrolled: N/A
    Study Sites: N/A Sites per country

    Anticipated completion date: N/A
    Scope of the Study / Aim: N/A

  • Regulatory Information

    Regulatory Information

    Status: Authorised

Update: 30 September 2023

  • No update available.


Update: 30 June 2023

  • Health Canada has approved Ferriprox® extended-release (twice daily) tablets (1,000mg) for patients with transfusional iron overload due to thalassemia, when current chelation therapy is inadequate, or SCD or other anaemias.

Ferriprox® was previously approved in Canada for the treatment of patients with transfusional iron overload due to thalassemia when current chelation therapy is inadequate in 2015, and subsequently approved for the treatment of iron overload in patients with SCD or other anemias in 2021.

Source: https://www.prnewswire.com/news-releases/chiesi-global-rare-diseases-announcesapproval-of-ferriprox-mr-deferiprone-extended-release-tablets-in-canada301787472.html 


Update: 31 March 2023

No update available.

Less than a minute
Back to top button